CN114929709B - 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 - Google Patents

螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 Download PDF

Info

Publication number
CN114929709B
CN114929709B CN202080091113.0A CN202080091113A CN114929709B CN 114929709 B CN114929709 B CN 114929709B CN 202080091113 A CN202080091113 A CN 202080091113A CN 114929709 B CN114929709 B CN 114929709B
Authority
CN
China
Prior art keywords
methyl
spiro
acetamide
furo
pyridin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080091113.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN114929709A (zh
Inventor
N.杰农
K.M.古基安
L.张
Z.辛
J.韦塞尔斯
R.吉亚纳塔西奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen MA Inc filed Critical Biogen MA Inc
Publication of CN114929709A publication Critical patent/CN114929709A/zh
Application granted granted Critical
Publication of CN114929709B publication Critical patent/CN114929709B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202080091113.0A 2019-10-29 2020-10-28 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂 Active CN114929709B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962927268P 2019-10-29 2019-10-29
US62/927,268 2019-10-29
PCT/US2020/057740 WO2021086966A1 (en) 2019-10-29 2020-10-28 Spirocyclic o-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors

Publications (2)

Publication Number Publication Date
CN114929709A CN114929709A (zh) 2022-08-19
CN114929709B true CN114929709B (zh) 2024-08-30

Family

ID=73554493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080091113.0A Active CN114929709B (zh) 2019-10-29 2020-10-28 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂

Country Status (8)

Country Link
US (1) US12565504B2 (enExample)
EP (1) EP4051682A1 (enExample)
JP (1) JP2023501949A (enExample)
CN (1) CN114929709B (enExample)
AR (1) AR120324A1 (enExample)
TW (1) TW202130643A (enExample)
UY (1) UY38934A (enExample)
WO (1) WO2021086966A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022095971A1 (zh) * 2020-11-06 2022-05-12 上海医药集团股份有限公司 一种螺杂环类化合物、其制备方法及应用
WO2025247394A1 (zh) * 2024-05-31 2025-12-04 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用
CN119569746B (zh) * 2025-02-06 2025-05-13 纽欧申医药(上海)有限公司 含氮杂环化合物、其药物组合物及应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143222A (zh) * 2013-03-14 2015-12-09 默克专利有限公司 糖苷酶抑制剂
CN107912040A (zh) * 2014-10-10 2018-04-13 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5948807A (en) * 1997-09-03 1999-09-07 Regents Of The University Of Minnesota Spiroindanamines and Spiroindanimides
WO2007063385A2 (en) * 2005-12-01 2007-06-07 Pfizer Products Inc. Spirocyclic amine histamine-3 receptor antagonists
EP1847542A1 (en) * 2006-04-21 2007-10-24 Laboratorios del Dr. Esteve S.A. Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor
ATE486877T1 (de) 2006-12-29 2010-11-15 Hoffmann La Roche Azaspiroderivate
WO2010141074A2 (en) * 2009-06-01 2010-12-09 President And Fellows Of Harvard College O-glcnac transferase inhibitors and uses thereof
AU2012298949B2 (en) * 2011-08-25 2016-09-22 Merck Patent Gmbh Pyrano [3, 2 - D] [1, 3] thiazole as glycosidase inhibitors
US9051269B2 (en) 2011-11-18 2015-06-09 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
EP2780014A4 (en) 2011-11-18 2015-07-01 Constellation Pharmaceuticals Inc MODULATORS OF METHYL MODIFYING ENZYMES, COMPOSITIONS AND USES THEREOF
WO2013078320A1 (en) 2011-11-21 2013-05-30 Constellation Pharmaceuticals Modulators of methyl modifying enzymes, compositions and uses thereof
JP5989805B2 (ja) 2012-02-10 2016-09-07 コンステレーション・ファーマシューティカルズ・インコーポレイテッドＣｏｎｓｔｅｌｌａｔｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． メチル基変更酵素の調節物質、組成物及びその使用
MA38341B1 (fr) 2013-02-11 2018-11-30 Constellation Pharmaceuticals Inc Modulateurs d'enzymes de modification par méthylation, compositions et utilisations associées
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
US9969716B2 (en) 2013-08-15 2018-05-15 Constellation Pharmaceuticals, Inc. Indole derivatives as modulators of methyl modifying enzymes, compositions and uses thereof
NZ727185A (en) * 2014-06-24 2018-04-27 Gilead Sciences Inc Phosphatidylinositol 3-kinase inhibitors
SMT202100699T1 (it) * 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
US11186564B2 (en) * 2016-08-04 2021-11-30 Sunovion Pharmaceuticals Inc. Dual NAV1.2/5HT2a inhibitors for treating CNS disorders
AU2018216040A1 (en) 2017-02-06 2019-06-20 Janssen Pharmaceutica Nv OGA inhibitor compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143222A (zh) * 2013-03-14 2015-12-09 默克专利有限公司 糖苷酶抑制剂
CN107912040A (zh) * 2014-10-10 2018-04-13 基因泰克公司 作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物

Also Published As

Publication number Publication date
WO2021086966A1 (en) 2021-05-06
TW202130643A (zh) 2021-08-16
US12565504B2 (en) 2026-03-03
US20230060003A1 (en) 2023-02-23
CN114929709A (zh) 2022-08-19
EP4051682A1 (en) 2022-09-07
AR120324A1 (es) 2022-02-09
UY38934A (es) 2021-05-31
JP2023501949A (ja) 2023-01-20

Similar Documents

Publication Publication Date Title
US7439251B2 (en) Methods and compositions for treatment of central and peripheral nervous system disorders and novel compounds useful therefor
TWI877697B (zh) 作為parp7抑制劑的嗒酮
CN114929709B (zh) 螺环o-糖蛋白-2-乙酰胺基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
KR20250035623A (ko) 척추소뇌성 운동실조증 유형 3을 치료하기 위한 화합물
US20100317850A1 (en) Condensed aminodihydrothiazine derivative
EP2389383B1 (en) Bicyclic heterocyclic spiro compounds
EP3083599A1 (en) Pyrazole derivatives and uses thereof as inhibitors of dlk
US20140328805A1 (en) Biheteroaryl compounds and uses thereof
CN118955490A (zh) O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃糖苷酶抑制剂
CN113166137B (zh) O-糖蛋白-2-乙酰氨基-2-脱氧-3-d-吡喃葡萄糖苷酶抑制剂
CA2825906A1 (en) Compounds for the reduction of .beta.-amyloid production
AU2016325665A1 (en) N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
IL323699A (en) KCC2 Potentiators and Their Uses
JP7213863B2 (ja) Ｐｄｅ７阻害剤としての置換ベンゾオキサゾール及びベンゾフラン化合物
EP4436661A1 (en) Spirocyclic cav2.3 antagonists
WO2025147603A1 (en) Thienopyridine compounds and uses thereof
WO2025126115A1 (en) Degradation of irak4 by conjugation of irak4 inhibitors with e3 ligase ligands and methods of use
WO2025096773A1 (en) Fabp7 inhibitors for the treatment of immunotherapy resistant tumors
CN121652168A (zh) 螺环化合物、其制备方法及用途
KR20250150141A (ko) 피리도피리미딘 유도체 및 이의 용도
IT202400001329A1 (it) Composti.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant